Molly Henderson - Jan 31, 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2022
Transactions value $
-$2,509
Form type
4
Date filed
2/2/2022, 03:34 PM
Previous filing
Dec 2, 2021
Next filing
Apr 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +666 +13.56% 5.58K Jan 31, 2022 Direct F1
transaction URGN Ordinary Shares Sale -$2.51K -331 -5.93% $7.58 5.25K Jan 31, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -666 -33.3% $0.00 1.33K Jan 31, 2022 Ordinary Shares 1.33K Direct F1, F3
transaction URGN Restricted Stock Units Award $0 +7.5K $0.00 7.5K Jan 31, 2022 Ordinary Shares 7.5K Direct F1, F4
transaction URGN Stock Option (right to buy) Award $0 +30K $0.00 30K Jan 31, 2022 Ordinary Shares 30K $7.72 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3 The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.
F5 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.